Compositions And Methods Of Treatment For Myocilin Glaucoma By Selectively Inhibiting Grp94

Abstract

A compound and method for treating myocilin glaucoma using a selective Grp94 inhibitor is presented. Clearance of mutant myocilin can be promoted by selectively targeting the endoplasmic reticulum (ER) chaperone Grp94 using siRNA knockdown or small molecule inhibitors. Grp94 contributes to the intracellular accumulation of mutant myocilin. Tailored treatments aimed at disrupting the Grp94/mutant myocilin interaction can be used as a new therapeutic strategy for myocilin glaucoma. The inventors developed a compound having a general backbone structure of geldanamycin (GDA) and radicicol (RDC) in which a more hydrophobic surrogate of the quinone in GDA is linked to the resorcinol in RDC through a cis-amide bioisostere.


Claims
Download PDF
Document Preview
Document History
  • Publication: Jun 2, 2015
  • Application: Nov 18, 2013
    US US 201314083031 A
  • Priority: Nov 18, 2013
    US US 201314083031 A
  • Priority: Nov 16, 2012
    US US 201261727561 P

Download Citation


Sign in to the Lens

Feedback